FUNDAMENTALS |
MarketCap: |
1.977 mill
|
EPS: |
-2.06
|
P/E: |
-0.138
|
Earnings Date: |
Apr 25, 2023 |
SharesOutstanding: |
6.93 mill
|
Avg Daily Volume: |
1.839 mill
|
RATING
2023-05-26 |
B+
|
Neutral
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Neutral
|
|
Return On Asset: |
Neutral
|
|
DE: |
Sell
|
|
P/E: |
Buy
|
|
Price To Book: |
Sell
|
|
QUARTER GROWTHS |
|
2/21 | 4/21 | 2/22 | 4/22 | 4/22 | 2/23 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
Asset | n/a | n/a | n/a | | n/a | |
Debt | n/a | n/a | n/a | | n/a | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -0.138 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
-0.02x
|
Company: PE -0.138 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.0766 - 0.187
( +/- 41.79%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2011-05-10 | Kiley Quinn Thomas | Buy | 1 000 | MLP & Strategic Equity Fund |
2010-10-06 | Zimmerman Gifford R | Buy | 0 | |
2010-10-06 | Toth Terence J | Buy | 0 | |
2010-10-06 | Schneider William J | Buy | 0 | |
2010-10-06 | Martin Larry W | Buy | 0 | |
INSIDER POWER |
0.00
|
Last
1 transactions |
Buy:
1 000 | Sell:
0 |
Forecast:
01:40 - $0.0980
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$0.285 (-18.50% )
|
Volume |
0.164 mill
|
Avg. Vol. |
1.839 mill
|
% of Avg. Vol |
8.94 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For MTP
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.